A campaign active since last November has been targeting Python developers building Telegram bots with trojanized Pyrogram ...

Vienna, Austria, June 25, 2026 — digna, the European data quality and observability platform, today announced the release of digna 2026.06, introducing a new Python SDK and Docker deployment support ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

One of the first moves Elon Musk made when he took over X, formerly Twitter, was to slap a $42,000-per-month price tag on the enterprise Twitter API, while neutering the capabilities of the API's ...

MILLBRAE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to ...

Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Eikon Therapeutics increased the ...

Eikon Therapeutics shares were down 6%, at $16.90, in the stock's first day of trade on the Nasdaq Global Select Market. Shares of the clinical-stage biopharmaceutical company began trading midday ...

Feb 5 (Reuters) - Drug developer Eikon Therapeutics , headed by Merck veteran Roger Perlmutter, was valued at about $860.3 million after its shares opened 5.3% below their offer price in their Nasdaq ...

Despite progress made in cancer immunotherapy, some patients don’t respond to these treatments or they stop responding after a period of time. Eikon Therapeutics’ lead drug candidate could address ...